abstract: BACKGROUND/PURPOSE: The aim of this study was to investigate the @entity2 - @entity4 (CFP-SUL) susceptibilities of important Gram-negative bacteria (GNB) by agar dilution (reference method), disk diffusion, and two automated methods. METHODS: A total of 799 GNB isolates, including Enterobacteriaceae (n  =  500) and nonfermentative GNB (NFGNB, n  =  299), were recovered from various clinical specimens collected at National Taiwan University Hospital, Taipei, Taiwan from November 2013 to December 2014. The agar dilution method, disk diffusion method, and two automated susceptibility systems (Phoenix and Vitek 2) were used for testing susceptibility of the isolates to CFP-SUL. Categories of susceptibility (susceptible, intermediate, or resistant) to CFP-SUL yielded from each method were interpreted according to CFP-SUL interpretive breakpoints proposed previously. The results of categorical agreement and errors obtained between the agar dilution method and the other three methods were analyzed. RESULTS: The Vitek 2 system had the highest error rates against @entity0 (n  =  150) and @entity5 (n  =  77) isolates, i.e., 6.7% and 11.7% minor errors, 8.5% and 1.7% major errors, and 40% and 20% very major errors, respectively. Additionally, the Vitek 2 system was also found to have a significantly lower sensitivity (44.4%) and lower positive predictive value (18.2%) for detecting CFP-SUL nonsusceptible @entity0 isolates than other methods. For @entity3 -nonsusceptible Enterobacteriaceae isolates, the Vitek 2 system failed to detect correct susceptibility to CFP-SUL. The three methods failed to correctly detect CFP-SUL susceptibility categories against all NFGNB isolates except @entity1 . CONCLUSION: The Vitek 2 system is a suboptimal method in correctly detecting CFP-SUL susceptibility categories for @entity0 , E. cloacae, and @entity3 -nonsusceptible Enterobacteriaceae isolates.

title: Comparison of commonly used antimicrobial susceptibility testing methods for evaluating susceptibilities of clinical isolates of Enterobacteriaceae and nonfermentative Gram-negative bacilli to XXXX - @entity4 .

answer: @entity2


abstract: BACKGROUND: @entity1 showing spontaneous @entity3 ( @entity3 )-like @entity2 were observed in the Kyoto Fancy @entity1 Stock 4 (KFRS4) strain breeding colony. OBJECTIVE: To establish the KFRS4 @entity1 as a model of @entity3 . METHODS: The clinical symptoms of @entity3 -like @entity2 were assessed by scoring the degree of @entity4 and examining scratching behavior. The transepidermal water loss was measured to evaluate skin barrier function. Cells infiltrating the @entity2 were identified using histological and immunohistological analyses. IgE and cytokine levels were measured to examine immune status. An ointment treatment experiment was carried out to characterize @entity4 in the KFRS4 @entity1 . RESULTS: @entity4 initially appeared around 4 months of age and rapidly worsened from 6 to 8 months of age. The @entity2 accompanied scratching behavior and were predominantly observed in females. The increased transepidermal water loss indicated @entity2 . Extensive infiltration of eosinophils, mast cells and lymphocytes was observed in the @entity2 . The plasma IgE level increased in accord with increasing severity of @entity4 . The Th2 and Th17 cytokine mRNA levels were significantly higher in the skin-draining lymph nodes than those in the non-skin-draining lymph nodes. It was demonstrated that @entity5 improved the symptoms of @entity4 . These findings demonstrated that @entity4 in the KFRS4 @entity1 closely resembled that seen in @entity0 @entity3 . CONCLUSION: Female KFRS4 @entity1 have the potential to serve as an animal model of @entity0 @entity3 .

title: XXXX with IgE hyperproduction and pruritus in KFRS4/Kyo @entity1 .

answer: @entity2


abstract: BACKGROUND: @entity1 showing spontaneous @entity3 ( @entity3 )-like @entity2 were observed in the Kyoto Fancy @entity1 Stock 4 (KFRS4) strain breeding colony. OBJECTIVE: To establish the KFRS4 @entity1 as a model of @entity3 . METHODS: The clinical symptoms of @entity3 -like @entity2 were assessed by scoring the degree of @entity4 and examining scratching behavior. The transepidermal water loss was measured to evaluate skin barrier function. Cells infiltrating the @entity2 were identified using histological and immunohistological analyses. IgE and cytokine levels were measured to examine immune status. An ointment treatment experiment was carried out to characterize @entity4 in the KFRS4 @entity1 . RESULTS: @entity4 initially appeared around 4 months of age and rapidly worsened from 6 to 8 months of age. The @entity2 accompanied scratching behavior and were predominantly observed in females. The increased transepidermal water loss indicated @entity2 . Extensive infiltration of eosinophils, mast cells and lymphocytes was observed in the @entity2 . The plasma IgE level increased in accord with increasing severity of @entity4 . The Th2 and Th17 cytokine mRNA levels were significantly higher in the skin-draining lymph nodes than those in the non-skin-draining lymph nodes. It was demonstrated that @entity5 improved the symptoms of @entity4 . These findings demonstrated that @entity4 in the KFRS4 @entity1 closely resembled that seen in @entity0 @entity3 . CONCLUSION: Female KFRS4 @entity1 have the potential to serve as an animal model of @entity0 @entity3 .

title: @entity2 with IgE hyperproduction and pruritus in KFRS4/Kyo XXXX .

answer: @entity1


abstract: BACKGROUND: The aim of this study was to analyze the usefulness of thyrotropin receptor messenger RNA ( @entity4 -mRNA) combined with neck ultrasonography (US) in the management of thyroid nodules with Bethesda III-V cytology. METHODS: Cytology slides of @entity0 with a preoperative fine needle aspiration (FNA) and @entity4 -mRNA who underwent thyroidectomy between 2002 and 2011 were recategorized based on the Bethesda classification. Results of thyroid FNA, @entity4 -mRNA, and US were compared with the final pathology. Sensitivity, specificity, positive predictive value ( @entity3 ), and negative predictive value (NPV) were calculated. RESULTS: There were 12 @entity0 with Bethesda III, 112 with Bethesda IV, and 58 with Bethesda V cytology. The sensitivity of @entity4 -mRNA in predicting @entity1 was 33%, 65%, and 79 %, and specificity was 67%, 66%, and 71%, for Bethesda III, IV, and V categories, respectively. For the same categories, the @entity3 of @entity4 -mRNA was 25%, 33%, and 79%, respectively; whereas the NPV was 75%, 88%, and 71%, respectively. The addition of neck US to @entity4 -mRNA increased the NPV to 100% for Bethesda III, and 86%, for Bethesda IV, and 82% for Bethesda V disease. CONCLUSION: This study documents the potential usefulness of @entity4 -mRNA for thyroid nodules with Bethesda III-V FNA categories. @entity4 -mRNA may be used to exclude @entity2 . A large sample analysis is needed to determine its accuracy for Bethesda category III nodules.

title: Diagnostic accuracy of circulating thyrotropin receptor messenger RNA  combined with neck ultrasonography in XXXX with Bethesda III-V thyroid cytology.

answer: @entity0


abstract: UNASSIGNED: The current study examines the efficacy of intensified group therapy for @entity1 with fear of blushing. Task concentration training (TCT) and cognitive therapy (CT) were applied during one weekend and compared with a waiting list condition in a randomized controlled trial including 82 @entity0 . On a second weekend, another intervention was added (resulting in TCT-CT and CT-TCT sequences) to examine order effects. Task concentration training and CT were both superior to the waiting list and equally effective after the first therapy weekend. Also, no differences were found between the sequences TCT-CT and CT-TCT at post-assessment. At 6- and 12-month follow-up, effects remained stable or further improved. At the 6-month follow-up, remission rates in completers, established by diagnostic status, were between 69% and 73%. Intensified group therapy is highly effective in treating @entity1 with fear of blushing. Group formats for @entity0 sharing a common primary concern may contribute to the dissemination of cognitive-behavioural therapy. Copyright    2015 John Wiley _ Sons, Ltd. Key Practitioner Message: This study focuses on blushing from fearful individuals within the @entity2 spectrum to improve evidence for treatment efficacy in those whose social fears are centred around observable bodily sensations. This study integrates task concentration training into the @entity2 model of Clark and Wells to combine two evidence-based treatments for @entity2 under one treatment model. This study uses an innovative format of brief, intensified group therapy, conducted on two full-day weekend group sessions delivered over two weekends, with strong observed effect sizes.

title: Cognitive Therapy and Task Concentration Training Applied as Intensified Group Therapies for XXXX with Fear of Blushing-A Randomized Controlled Trial.

answer: @entity1


abstract: UNASSIGNED: The European Organisation for Research and Treatment of @entity2 (EORTC) Quality of Life Questionnaire-Lung @entity2 13 (QLQ-LC13) covers 13 typical symptoms of @entity1 @entity0 and was the first module developed in conjunction with the EORTC core quality-of-life (QL) questionnaire. This review investigates how the module has been used and reported in @entity2 clinical trials in the 20 years since its publication. Thirty-six databases were searched with a prespecified algorithm. This search plus an additional hand search generated 770 hits, 240 of which were clinical studies. Two raters extracted data using a coding scheme. Analyses focused on the @entity3 ( @entity3 ). Of the 240 clinical studies that were identified using the LC13, 109 (45%) were @entity3 . More than half of the @entity3 were phase 3 trials (n   =   58). Twenty @entity3 considered QL as the primary endpoint, and 68 considered it as a secondary endpoint. QL results were addressed in the results section of the article (n   =   89) or in the abstract (n   =   92); and, in half of the articles, QL results were presented in the form of tables (n   =   53) or figures (n   =   43). Furthermore, QL results had an impact on the evaluation of the therapy that could be clearly demonstrated in the 47 @entity3 that yielded QL differences between treatment and control groups. The EORTC QLQ-LC13 fulfilled its mission to be used as a standard instrument in @entity1 clinical trials. An update of the LC13 is underway to keep up with new therapeutic trends and to ensure optimized and relevant QL assessment in future trials. @entity2 2015;121:4300-23.    2015 American @entity2 Society.

title: Use of the XXXX -specific Quality of Life Questionnaire EORTC QLQ-LC13 in clinical trials: A systematic review of the literature 20 years after its development.

answer: @entity1


abstract: OBJECTIVE: To assess downstream healthcare resource utilization (HRU) and costs among immediate release (IR) @entity1 @entity0 by days' supply and average doses/month in the prior 6 months. METHODS: Retrospective analysis using healthcare claims from Truven MarketScan commercial, Medicare supplemental, and Medicaid multistate databases was performed. @entity0 prescribed IR @entity1 during the 6-month baseline (July-December 2011), and with continuous enrollment during baseline and the 12-month follow-up (2012) were selected. HRU and per- @entity0 -per-month (PPPM) costs (2014 US dollars) were assessed at follow-up. Descriptive analyses and multivariate regressions were conducted to compare HRU and costs at follow-up by days' supply (<60 vs >= 60 days) and average doses per month ( <=60 vs >60 doses/month) of IR @entity1 at baseline. RESULTS: In total, 1,698,845 commercial, 264,038 Medicare, and 151,063 Medicaid IR @entity1 @entity0 were identified. During follow-up, commercial @entity0 with prior >= 60 days' supply were more likely to have an inpatient admission (13.2% vs 7.5%), outpatient hospital visit (69.1% vs 57.0%), office visit (97.6% vs 91.0%), emergency room (ER) visit (28.1% vs 21.4%), and had higher PPPM total costs ( 1494 vs  842) than the <60 days' supply sub-group (all p   <   0.05). Among commercial @entity0 the adjusted odds ratio for prior >= 60 days' supply of IR @entity1 vs prior <60 days' supply was 1.62 (inpatient), 1.33 (outpatient), 2.58 (office visit) and 1.48 (ER) (all p-values <0.05). Adjusted all-cause total costs were higher ( 1245 vs  851, p <0.05) among commercial @entity0 with longer days' supply than those with shorter days' supply. Trends were similar with  <=60 vs >60 doses per month sub-groups and across all plan types. CONCLUSION: Increased days' supply and higher doses/month of IR @entity1 in the prior 6 months may help to predict levels of HRU and costs in the following year, providing an opportunity to identify @entity0 in order to implement interventions to improve their quality of care.

title: Characterizing downstream healthcare resource utilization and costs based on prior utilization patterns of immediate-release XXXX .

answer: @entity1


abstract: UNASSIGNED: OBJECT To determine the incidence of and assess the risk factors associated with @entity0 in motor vehicle occupants who sustain @entity3 of the thoracolumbar spine. METHODS In this study, the authors queried medical, vehicle, and crash data elements from the Crash Injury Research and Engineering Network (CIREN), a prospectively gathered multicenter database compiled from Level I @entity2 centers. Subjects had @entity3 involving the T1-L5 vertebral segments, an @entity2 ( @entity2 ) score of >=  3, or @entity2 with an @entity2 score of >=  2 in each region. Demographic parameters obtained for all subjects included age, sex, height, body weight, and body mass index. Clinical parameters obtained included the level of the injured vertebra and the level and type of @entity4 . Vehicular crash data included vehicle make, seatbelt type, and usage and appropriate use of the seatbelt. Crash data parameters included the principal direction of force, change in velocity on impact (  V), airbag deployment, and vehicle rollover. The authors performed a univariate analysis of the incidence and the odds of sustaining spinal @entity0 associated with @entity3 with respect to the demographic, clinical, and crash parameters. RESULTS Neurological deficit associated with thoracolumbar @entity3 was most frequent at extremes of age; the highest rates were in the 0- to 10-year (26.7% [4 of 15]) and 70- to 80-year (18.4% [7 of 38]) age groups. Underweight occupants (OR 3.52 [CI 1.055-11.7]) and @entity1 occupants (OR 3.27 [CI 1.28-8.31]) both had higher odds of sustaining @entity4 than occupants with a normal body mass index. The highest risk of @entity0 existed in crashes in which airbags deployed and the occupant was not restrained by a seatbelt (OR 2.35 [CI 0.087-1.62]). Reduction in the risk of @entity0 occurred when 3-point seatbelts were used correctly in conjunction with the deployment of airbags (OR 0.34 [CI 1.3-6.6]) compared with the occupants who were not restrained by a seatbelt and for whom airbags were not deployed. Crashes with a   V greater than 50 km/hour had a significantly higher risk of @entity4 (OR 3.45 [CI 0.136-0.617]) than those at lower   V values. CONCLUSIONS Deployment of airbags was protective against @entity0 only when used in conjunction with 3-point seatbelts. @entity5 who were either @entity1 or underweight, very young or elderly, and those in crashes with a   V greater than 50 km/hour were at higher risk of thoracolumbar @entity0 . @entity0 at thoracic and lumbar levels was associated with multiple factors, including the incidence of fatality, occupant factors such as age and body habitus, energy at impact, and direction of impact. Current vehicle safety technologies are geared toward a normative body morphology and need to be reevaluated for various body morphologies and torso compliances to lower the risk of @entity0 resulting from thoracolumbar @entity3 .

title: Incidence and mechanism of neurological deficit after thoracolumbar XXXX sustained in motor vehicle collisions.

answer: @entity3


abstract: UNASSIGNED: Background: The clinical presentation of spondylsodiscitis/ @entity1 are manifold. This commonly leads to a period of several months from initial symptoms to final diagnosis. A standardised treatment is difficult. The purpose of this study is to investigate the treatment carried out for @entity0 with @entity2 or @entity1 to develop an individualised standard care for better treatment. @entity0 and Methods: Data of 90 @entity0 were retrospective analysed. In particular documented data of the initial examination and the following treatments concerning identification of causes and systematically control of pathogens were examined. Results: In 91% of @entity0 a diagnostically conclusive MRI was conducted. The degree of spondylidiscitis/ @entity1 was mainly ASA criteria I or II (86%). In 96% of @entity0 different diagnostic methods for identification of pathogens were conducted and documented. Results confirmed the most common pathogens mentioned in the literature. 75% of @entity0 were treated by surgery. In 93% of patients an antibiotic treatment was documented. 50 @entity0 (81%) were successfully healed. Conclusion: It is important to identify and treat @entity2 / @entity1 as early as possible. Diagnosis by means of blood culture and MRI and treatment of the infection with antibiotics and possibly surgical interventions seem be very suitable, but need to be individualised to each and every @entity0 .

title: [Diagnosis and Treatment of XXXX /Spondylitis in Clinical Practice].

answer: @entity2


abstract: The C6 spheroid implantation @entity1 model is a simple, easily reproduced model for @entity1 in which C6 @entity5 cells are grown in vitro as spheroids and subsequently implanted into the brains of @entity2 hosts. This report describes the growth, histology, vessel architecture and vascular permeability of the resulting @entity0 . The appearance of the @entity0 was investigated by light and electron microscopy, and by using the alkaline phosphatase technique. The leakage of tracer was measured from vessels in the @entity0 and peritumoral area at various times during @entity0 development. The spheroid implant produces a fully vascularized, rapidly growing @entity0 with many of the characteristics of @entity4 multiforme, from an avascular focus of neoplastic cells. The major advantage of this model is that the @entity0 grow in a spheroidal fashion and the @entity0 -brain interface can be easily located. Many of the important events in the process of vascularization take place at the @entity0 -brain interface. Two distinctive vascular events appear to occur simultaneously: proliferation of blood vessels and their growth into the @entity0 mass so that they develop into typical, permeable @entity0 vessels, and migration of @entity0 cells along normal vessels into the surrounding brain. Tumor vessels were permeable to the tracer Evans Blue (EB) from the earliest days of ingrowth. Leakage of the EB increased as the @entity0 increased in size, but eventually leakage plateaued as @entity0 developed @entity3 centers. It is well known that the structural and permeability characteristics of vessels associated with the @entity0 affect @entity0 growth. This model will be useful for a number of proposed studies including assessment of various clinical therapies on @entity0 growth and development, and more specifically, quantitative analysis of the vascularization process in @entity0 .

title: A new XXXX model in @entity2 : the C6 spheroid implantation technique permeability and vascular characterization.

answer: @entity1


abstract: The C6 spheroid implantation @entity1 model is a simple, easily reproduced model for @entity1 in which C6 @entity5 cells are grown in vitro as spheroids and subsequently implanted into the brains of @entity2 hosts. This report describes the growth, histology, vessel architecture and vascular permeability of the resulting @entity0 . The appearance of the @entity0 was investigated by light and electron microscopy, and by using the alkaline phosphatase technique. The leakage of tracer was measured from vessels in the @entity0 and peritumoral area at various times during @entity0 development. The spheroid implant produces a fully vascularized, rapidly growing @entity0 with many of the characteristics of @entity4 multiforme, from an avascular focus of neoplastic cells. The major advantage of this model is that the @entity0 grow in a spheroidal fashion and the @entity0 -brain interface can be easily located. Many of the important events in the process of vascularization take place at the @entity0 -brain interface. Two distinctive vascular events appear to occur simultaneously: proliferation of blood vessels and their growth into the @entity0 mass so that they develop into typical, permeable @entity0 vessels, and migration of @entity0 cells along normal vessels into the surrounding brain. Tumor vessels were permeable to the tracer Evans Blue (EB) from the earliest days of ingrowth. Leakage of the EB increased as the @entity0 increased in size, but eventually leakage plateaued as @entity0 developed @entity3 centers. It is well known that the structural and permeability characteristics of vessels associated with the @entity0 affect @entity0 growth. This model will be useful for a number of proposed studies including assessment of various clinical therapies on @entity0 growth and development, and more specifically, quantitative analysis of the vascularization process in @entity0 .

title: A new @entity1 model in XXXX : the C6 spheroid implantation technique permeability and vascular characterization.

answer: @entity2


abstract: The in vitro protein binding behavior of @entity1 ( @entity3 ) in plasma and synovial fluid was investigated by equilibrium dialysis. The drug was highly protein bound (approximately 99.5%) and the extent of binding remained constant for drug concentrations of 2-10 micrograms/mL. Comparable results were obtained with human serum albumin solution (45 g/L) indicating that albumin is probably the responsible protein. The extent of binding remained relatively constant for drug concentrations of 0.25-10 micrograms/mL when albumin concentrations were greater than 25 g/L. For albumin concentrations less than 10 g/L, the extent of binding tended to decrease with increased drug concentration. This concentration (10 g/L) is substantially lower than that usually observed in plasma or synovial fluid of arthritic @entity0 . Curvature of the Scatchard plot indicated the existence of two classes of sites. Excellent results were obtained from fitting of the data according to two classes of sites (r2 greater than 0.999). Parameter estimates (SEM) of the number of binding sites, n1 and n2, and the corresponding association constants, k1 and k2, were 2.26 (0.55), 10.20 (0.69), and 1.32 (0.54) X 10(5) @entity2 , and 3.71 (1.11) X 10(3) @entity2 , respectively. Simultaneous samples obtained from arthritic @entity0 indicate considerably higher total protein and albumin concentrations in plasma compared with synovial fluid, but the albumin:total protein ratios were essentially the same. There was very little difference in plasma binding in arthritic @entity0 compared with normal subjects. The extent of binding in synovial fluid samples was consistently lower than that for plasma samples (mean +/- SD of 99.5 +/- 0.2% versus 99.7 +/- 0.1%, respectively).(ABSTRACT TRUNCATED AT 250 WORDS)

title: In vitro protein binding of XXXX in plasma and synovial fluid.

answer: @entity1


abstract: BACKGROUND: Bleeding complications increase mortality in @entity2 @entity0 . Potential gender difference in @entity1 regarding prevalence and prognostic impact is still controversial. OBJECTIVES: Gender comparison regarding incidence and prognostic impact of @entity1 in @entity0 hospitalised with @entity2 during 2006-2008. METHODS: Observational study from the SWEDEHEART register. Outcomes were in-hospital bleedings, in-hospital mortality and one-year mortality in hospital survivors. RESULTS: A total number of 50,399 @entity2 @entity0 were included, 36.6% @entity0 . In-hospital bleedings were more common in @entity0 (1.9% vs. 3.1%, p<0.001) even after multivariable adjustment ( @entity3 , 95% confidence interval (CI) 1.01-1.37). The increased risk for @entity0 was found in ST-elevation @entity2 (OR 1.46, 95% CI 1.10-1.94) and in those who underwent percutaneous coronary intervention (OR 1.80, 95% CI 1.45-2.24). In contrast the risk was lower in medically treated @entity0 (OR 0.79, 95% CI 0.62-1.00). After adjustment, in-hospital @entity1 was associated with higher risk of one-year mortality in @entity0 (OR 1.35, 95% CI 1.04-1.74), whereas this was not the case in @entity0 (OR 0.97, 95% CI 0.72-1.31). CONCLUSIONS: Female gender is an independent risk factor of in-hospital @entity1 after @entity2 . A higher @entity1 risk in @entity0 appeared to be restricted to invasively treated @entity0 and ST-elevation @entity2 @entity0 . Even though @entity0 have higher short- and long-term mortality, there was no difference between the genders among bleeders. After multivariable adjustment the prognostic impact of @entity1 complications was higher in @entity0 .

title: Gender difference in prognostic impact of in-hospital XXXX after @entity2 - data from the SWEDEHEART registry.

answer: @entity1


abstract: BACKGROUND: Bleeding complications increase mortality in @entity2 @entity0 . Potential gender difference in @entity1 regarding prevalence and prognostic impact is still controversial. OBJECTIVES: Gender comparison regarding incidence and prognostic impact of @entity1 in @entity0 hospitalised with @entity2 during 2006-2008. METHODS: Observational study from the SWEDEHEART register. Outcomes were in-hospital bleedings, in-hospital mortality and one-year mortality in hospital survivors. RESULTS: A total number of 50,399 @entity2 @entity0 were included, 36.6% @entity0 . In-hospital bleedings were more common in @entity0 (1.9% vs. 3.1%, p<0.001) even after multivariable adjustment ( @entity3 , 95% confidence interval (CI) 1.01-1.37). The increased risk for @entity0 was found in ST-elevation @entity2 (OR 1.46, 95% CI 1.10-1.94) and in those who underwent percutaneous coronary intervention (OR 1.80, 95% CI 1.45-2.24). In contrast the risk was lower in medically treated @entity0 (OR 0.79, 95% CI 0.62-1.00). After adjustment, in-hospital @entity1 was associated with higher risk of one-year mortality in @entity0 (OR 1.35, 95% CI 1.04-1.74), whereas this was not the case in @entity0 (OR 0.97, 95% CI 0.72-1.31). CONCLUSIONS: Female gender is an independent risk factor of in-hospital @entity1 after @entity2 . A higher @entity1 risk in @entity0 appeared to be restricted to invasively treated @entity0 and ST-elevation @entity2 @entity0 . Even though @entity0 have higher short- and long-term mortality, there was no difference between the genders among bleeders. After multivariable adjustment the prognostic impact of @entity1 complications was higher in @entity0 .

title: Gender difference in prognostic impact of in-hospital @entity1 after XXXX - data from the SWEDEHEART registry.

answer: @entity2


abstract: UNASSIGNED: The infrapatellar fat pad (IFP) secretes inflammatory mediators in osteoarthritic knees, but the effect of aging on IFP @entity2 is unknown. We tested the hypothesis that aging increases basal and @entity6 ( @entity6 )-stimulated IFP @entity2 in 10-, 20-, and 30-month-old male F344BN F1-hybrid @entity3 . IFPs were cultured ex vivo for 24 hours and treated   1ng/mL @entity6 to simulate injury-induced @entity2 . IFP @entity2 was evaluated by measuring secreted cytokine concentrations and by quantitative expression of immunoregulatory and pro- and anti-adipogenic genes. With age, @entity5 pathology increased and IFP mass decreased. Although adipocyte size did not change with age, variation in adipocyte size was positively associated with synovial thickness independent of age whereas associations with @entity1 were age dependent. In the absence of @entity6 , aging was associated with a significant increase in IFP secretion of @entity0 @entity4 factor a by 67% and @entity7 by 35% and a reduction in the expression of immunoregulatory M2 macrophage genes. However, following an @entity6 challenge, adipogenesis markers decreased and pro- and anti-inflammatory cytokines increased independent of age. The lone exception was leptin, which decreased >70% with age. Thus, although aging promotes @entity5 risk by increasing basal @entity2 , our findings also revealed a potentially protective effect of aging by decreasing @entity6 -stimulated leptin production.

title: Effect of Aging on Adipose Tissue Inflammation in the Knee Joints of F344BN XXXX .

answer: @entity3


abstract: BACKGROUND: Nonpharmacological interventions have been shown to have some effectiveness in adults with @entity2 ; however, the effectiveness of these interventions in older @entity0 is unknown. PURPOSE: The aim of this study was to determine the effects of conservative nonpharmacological interventions for @entity2 in older @entity0 . DATA SOURCES: The Cochrane Central Register of Controlled Trials, PubMed, EMBASE, SCOPUS, CINAHL, AMED, Index to Chiropractic Literature, PsycINFO, and MANTIS were searched from inception to May 2014. STUDY SELECTION: Two investigators independently screened controlled trials with @entity0 who were more than 60 years old and experienced @entity2 . Studies of @entity0 with @entity2 from a specific diagnosis, such as M  ni  re disease and @entity1 , were excluded. Outcome measures from the selected studies included self-reported @entity2 and postural balance. DATA EXTRACTION: Two investigators independently extracted data on @entity0 , interventions, comparison group, outcome measures, and results. The risk of bias of the included studies was assessed with Cochrane guidelines. DATA SYNTHESIS: Seven articles consisting of 7 controlled trials were included. All studies involved some form of exercise, including vestibular rehabilitation exercises, postural balance exercises, and tai chi exercise, as the main intervention. The studies had a high risk of bias because of the lack of adequate randomization and allocation concealment, the lack of reporting on cointerventions, the lack of reporting on reasons for dropouts, and the lack of reporting on @entity0 adherence. LIMITATIONS: Heterogeneity among the included studies in interventions and outcome measures prohibited a meta-analysis. Only 2 studies reported a significant difference between the intervention group and the comparison group for self-reported @entity2 . CONCLUSIONS: There is insufficient evidence to determine the effectiveness of nonpharmacological treatments for @entity2 in older @entity0 . Current evidence is hampered by a high risk of bias, and well-designed trials with adequate masking, randomization, and adherence are needed.

title: Effects of Nonpharmacological Interventions for Dizziness in Older XXXX : Systematic Review.

answer: @entity0


abstract: BACKGROUND AND PURPOSE: The term @entity3 describes the clustering of risk factors found in many individuals with @entity1 . Because of their pathophysiology, we hypothesized that 2 features of @entity3 , @entity5 and @entity6 resistance (IR), would be associated with cerebrovascular changes on magnetic resonance imaging, and specifically with incident @entity2 and not white matter hyperintensity (WMH) progression. METHODS: Risk factors were defined at study baseline in 934 @entity0 in the @entity4 Risk in Communities (ARIC) study, who completed 2 brain magnetic resonance imagings   10 years apart. WMH progression and incident lacunes between the 2 magnetic resonance imagings were determined. An IR score for each @entity0 was created using principal component analysis of 11 risk factors, including (among others): @entity6 , homeostatic model assessment-IR, body mass index, and waist circumference. @entity3 (presence/absence), using standard clinical definitions, and IR score at the first magnetic resonance imaging, were independent variables, evaluated in multivariate logistic regression to determine odds of WMH progression (Q5 versus Q1-Q4) and incident lacunes. RESULTS: @entity3 (adjusted odds ratio, 1.98; 95% confidence interval, 1.28-3.05) and IR score (adjusted odds ratio per 1-SD increase, 1.33; 95% confidence interval, 1.05-1.68) were associated with incident lacunes but not with WMH progression. @entity6 , homeostatic model assessment-IR, and body mass index were not associated with incident lacunes or WMH progression in separate models. CONCLUSIONS: The IR score and @entity5 are associated with incident @entity2 but not WMH progression in individuals. @entity5 and IR may be important risk factors to target to prevent @entity2 .

title: XXXX , @entity6 Resistance, and Incident Small Vessel Disease on Magnetic Resonance Imaging: @entity4 Risk in Communities Study.

answer: @entity1


abstract: BACKGROUND AND PURPOSE: The term @entity3 describes the clustering of risk factors found in many individuals with @entity1 . Because of their pathophysiology, we hypothesized that 2 features of @entity3 , @entity5 and @entity6 resistance (IR), would be associated with cerebrovascular changes on magnetic resonance imaging, and specifically with incident @entity2 and not white matter hyperintensity (WMH) progression. METHODS: Risk factors were defined at study baseline in 934 @entity0 in the @entity4 Risk in Communities (ARIC) study, who completed 2 brain magnetic resonance imagings   10 years apart. WMH progression and incident lacunes between the 2 magnetic resonance imagings were determined. An IR score for each @entity0 was created using principal component analysis of 11 risk factors, including (among others): @entity6 , homeostatic model assessment-IR, body mass index, and waist circumference. @entity3 (presence/absence), using standard clinical definitions, and IR score at the first magnetic resonance imaging, were independent variables, evaluated in multivariate logistic regression to determine odds of WMH progression (Q5 versus Q1-Q4) and incident lacunes. RESULTS: @entity3 (adjusted odds ratio, 1.98; 95% confidence interval, 1.28-3.05) and IR score (adjusted odds ratio per 1-SD increase, 1.33; 95% confidence interval, 1.05-1.68) were associated with incident lacunes but not with WMH progression. @entity6 , homeostatic model assessment-IR, and body mass index were not associated with incident lacunes or WMH progression in separate models. CONCLUSIONS: The IR score and @entity5 are associated with incident @entity2 but not WMH progression in individuals. @entity5 and IR may be important risk factors to target to prevent @entity2 .

title: @entity1 , XXXX Resistance, and Incident Small Vessel Disease on Magnetic Resonance Imaging: @entity4 Risk in Communities Study.

answer: @entity6


abstract: BACKGROUND AND PURPOSE: The term @entity3 describes the clustering of risk factors found in many individuals with @entity1 . Because of their pathophysiology, we hypothesized that 2 features of @entity3 , @entity5 and @entity6 resistance (IR), would be associated with cerebrovascular changes on magnetic resonance imaging, and specifically with incident @entity2 and not white matter hyperintensity (WMH) progression. METHODS: Risk factors were defined at study baseline in 934 @entity0 in the @entity4 Risk in Communities (ARIC) study, who completed 2 brain magnetic resonance imagings   10 years apart. WMH progression and incident lacunes between the 2 magnetic resonance imagings were determined. An IR score for each @entity0 was created using principal component analysis of 11 risk factors, including (among others): @entity6 , homeostatic model assessment-IR, body mass index, and waist circumference. @entity3 (presence/absence), using standard clinical definitions, and IR score at the first magnetic resonance imaging, were independent variables, evaluated in multivariate logistic regression to determine odds of WMH progression (Q5 versus Q1-Q4) and incident lacunes. RESULTS: @entity3 (adjusted odds ratio, 1.98; 95% confidence interval, 1.28-3.05) and IR score (adjusted odds ratio per 1-SD increase, 1.33; 95% confidence interval, 1.05-1.68) were associated with incident lacunes but not with WMH progression. @entity6 , homeostatic model assessment-IR, and body mass index were not associated with incident lacunes or WMH progression in separate models. CONCLUSIONS: The IR score and @entity5 are associated with incident @entity2 but not WMH progression in individuals. @entity5 and IR may be important risk factors to target to prevent @entity2 .

title: @entity1 , @entity6 Resistance, and Incident Small Vessel Disease on Magnetic Resonance Imaging: XXXX Risk in Communities Study.

answer: @entity4


abstract: BACKGROUND: To improve the prognosis of @entity0 with @entity3 , new biomarkers are required for earlier, pre-symptomatic diagnosis. Epigenetic mutations take place at the earliest stages of tumorigenesis and therefore offer new approaches for detecting and diagnosing disease. Nucleosomes are the repeating subunits of DNA and histone proteins that constitute @entity0 chromatin. Because of their release into the circulation, intact nucleosome levels in serum or plasma can serve as diagnostic disease biomarkers, and elevated levels have been reported in various @entity1 . However, quantifying nucleosomes in the circulation for @entity1 detection has been challenging due to nonspecific elevation in sera of @entity0 with benign diseases. Here, we report for the first time differential, disease-associated epigenetic profiles of intact cell-free nucleosomes (cfnucleosomes) containing specific DNA and histone modifications as well as histone variants circulating in the blood. The study comprised serum samples from 59 individuals, including 25 @entity0 with resectable @entity3 , 10 @entity0 with benign @entity2 , and 24 healthy individuals using Nucleosomics(  ), a novel ELISA method. RESULTS: Multivariate analysis defined a panel of five serum cfnucleosome biomarkers that gave an area under the curve (AUC) of 0.95 for the discrimination of @entity3 from healthy controls, which was superior to the diagnostic performance of the common @entity3 biomarker, @entity4 antigen 19-9 (CA 19-9) with an AUC of 0.87. Combining CA 19-9 with a panel of four cfnucleosome biomarkers gave an AUC of 0.98 with an overall sensitivity of 92  % at 90  % specificity. CONCLUSIONS: The present study suggests that global epigenetic profiling of cfnucleosomes in serum using a simple NuQ(  ) immunoassay-based approach can provide novel diagnostic biomarkers in @entity3 .

title: Circulating nucleosomes as epigenetic biomarkers in XXXX .

answer: @entity3


abstract: The @entity3 ( @entity3 ) @entity0 models are commonly used for studying the @entity2 . The impact parameters vary considerably among different laboratories, making the comparison of research findings difficult. In this work, numerical @entity3 experiments were conducted to investigate the sensitivities of intracranial responses to various impact parameters (e.g., impact depth, velocity, and position; impactor diameter, material, and shape). A three-dimensional finite element @entity0 head model with anatomical details was subjected to impact loadings. Results revealed that impact depth and impactor shape were the two leading factors affecting intracranial responses. The influence of impactor diameter was region-specific and an increase in impactor diameter could substantially increase tissue strains in the region which located directly beneath the impactor. The lateral impact could induce higher strains in the brain than the central impact. An indentation depth instead of impact depth would be appropriate to characterize the influence of a large deformed rubber impactor. The experimentally observed velocity-dependent @entity1 could be attributed to the "overshoot" phenomenon. This work could be used to better design or compare @entity3 experiments.

title: Characterization of Closed Head Impact Injury in XXXX .

answer: @entity0


abstract: BACKGROUND: @entity3 with or without @entity2 ( @entity5 /P) is among the most common @entity1 . The etiology of @entity5 /P remains poorly characterized owing to its complex genetic heterogeneity. The objective of this study was to identify genetic variants that increase susceptibility to @entity5 /P. MATERIAL AND METHODS: Whole-exome sequencing (WES) was performed in 8 fetuses with @entity5 /P in China. Bioinformatics analysis was performed using commercially available software. Variants detected by WES were validated by Sanger sequencing. RESULTS: By filtering out synonymous variants in exons, we identified average 8575 nonsynonymous single @entity4 variants (SNVs). We subsequently compared the SNVs against public databases including NCBI dbSNP build 135 and 1000 Genomes Project and obtained an average of 203 SNVs. Total 12 reported candidate genes were verified by Sanger sequencing. Sanger sequencing also confirmed 16 novel SNVs shared by two or more samples. CONCLUSIONS: We have found and confirmed 16 susceptibility genes responsible for @entity5 /P, which may play important role in the etiology of @entity5 /P. The susceptibility genes identified in this study will not only be useful in revealing the etiology of @entity5 /P but also in diagnosis and treatment of the @entity0 with @entity5 /P.

title: Identification of susceptibility genes in @entity3 with or without XXXX using whole-exome sequencing.

answer: @entity2


abstract: BACKGROUND: @entity3 with or without @entity2 ( @entity5 /P) is among the most common @entity1 . The etiology of @entity5 /P remains poorly characterized owing to its complex genetic heterogeneity. The objective of this study was to identify genetic variants that increase susceptibility to @entity5 /P. MATERIAL AND METHODS: Whole-exome sequencing (WES) was performed in 8 fetuses with @entity5 /P in China. Bioinformatics analysis was performed using commercially available software. Variants detected by WES were validated by Sanger sequencing. RESULTS: By filtering out synonymous variants in exons, we identified average 8575 nonsynonymous single @entity4 variants (SNVs). We subsequently compared the SNVs against public databases including NCBI dbSNP build 135 and 1000 Genomes Project and obtained an average of 203 SNVs. Total 12 reported candidate genes were verified by Sanger sequencing. Sanger sequencing also confirmed 16 novel SNVs shared by two or more samples. CONCLUSIONS: We have found and confirmed 16 susceptibility genes responsible for @entity5 /P, which may play important role in the etiology of @entity5 /P. The susceptibility genes identified in this study will not only be useful in revealing the etiology of @entity5 /P but also in diagnosis and treatment of the @entity0 with @entity5 /P.

title: Identification of susceptibility genes in XXXX with or without @entity2 using whole-exome sequencing.

answer: @entity3


abstract: BACKGROUND: @entity1 -related subclavian and axillary @entity5 (SAVIs) are generally associated with high morbidity and mortality rates in the surgical literature. There is an emerging trend towards increasing use of stent grafts (covered stents) for repair, with evidence limited to small case series and case reports. OBJECTIVES: To report on the clinical and device-related outcomes of stent graft repair of @entity1 -related SAVIs at a single institution. METHODS: A retrospective chart review of all @entity0 with @entity1 -related SAVIs requiring stent graft repair was performed. Outcome measures included technical success, mortality, amputation rate, device-related complications (early and late), and reintervention rates (early and late). RESULTS: A total of 31 @entity0 was identified between June 2008 and October 2013 (30 males, 1 female). Mean age was 27.9 years (range 19 - 51). All 31 @entity0 sustained a @entity7 (93.5% stab, 6.5% gunshot injuries). There were 21 subclavian and 10 axillary @entity5 . Five @entity0 (16%) were @entity3 -positive. Nine @entity0 (29%) were shocked on presentation. Early results (30 days): There were no periprocedural @entity2 . Primary technical success was 83.9% (26/31). Five @entity0 required adjunctive interventional or operative procedures. There were no early procedure-related complications, reinterventions or open conversions in this study. Overall, suboptimal results were seen in five @entity0 (one type I endoleak and four @entity4 ). Follow-up results (>30 days): Nineteen @entity0 (61.3%) were available for follow-up. Mean duration of follow-up was 55.7 weeks (range 4 - 240). Overall stent graft patency was 89.5% (17/19). Four @entity0 (21.1%) had an occluded stent graft. Stent graft salvage was possible in two @entity0 . Three @entity4 were seen on follow-up. Late reinterventions were performed in five @entity0 (26.3%). Conversion to an open procedure was not required in any @entity0 . There was one late death and one major amputation of a stented limb in a @entity0 who had sustained severe soft-tissue injuries during the follow-up period. CONCLUSION: Perioperative, early and intermediate results suggest that stent graft repair of select @entity1 -related SAVIs is relatively safe and effective. Axillary @entity6 remain a particular challenge using this treatment modality. Larger prospective studies are required to define the utility of stent grafts for select @entity1 -related SAVIs better.

title: Stent graft repair of subclavian and axillary XXXX : The Groote Schuur experience.

answer: @entity5


abstract: Entire bucks (N = 7) exhibited pronounced liveweight gains over spring and summer months (October-February), to reach a peak mean weight of 59.8 kg, and rapid liveweight losses over the rutting period (April-May) with a minimum mean liveweight of 54.2 kg. Mean neck girth and serum @entity0 levels increased during late summer (January-March) and peaked at 387 mm and 12 ng/ml respectively immediately before the onset of the rut (April). Thereafter both measures declined during winter and spring months (June-December). Bucks castrated prepubertally (N = 11) exhibited similar but less pronounced changes in mean liveweight and neck girth, in the absence of any change in @entity0 secretion. Peak mean testicular diameter of entire bucks (39 mm) occurred immediately before the rut and was followed by testicular regression over winter and spring months (June-November), such that the testes attained their minimum mean size of 18 mm diameter in early summer (November). Motile spermatozoa were absent from ejaculates collected in summer (November 1983, 1984; January 1984). However, ejaculates collected pre-rut (late March), immediately post-rut (June) and in early spring (September) contained successively increasing numbers of motile spermatozoa. A further 14 polled, entire bucks were given orally 5 mg (N = 7; Group A) or 20 mg (N = 7; Group B) @entity1 at 15:30 h daily from 1 December 1983 to 14 January 1984 (45 days). Seven control bucks (Group C) received vehicle ration only. The measurements taken for bucks in Groups A and B were not significantly different (P greater than 0.1) on any sampling date and the data for these 2 groups were pooled. Mean serum @entity0 concentrations and mean ejaculate volume were not significantly different between @entity1 -treated and control bucks on any sampling date, although other measures exhibited significant differences (P less than 0.05) at various treatment or post-treatment dates: @entity1 -treated bucks showed a transiently greater increase in neck muscle development during and immediately after treatment, a slight retardation of liveweight gain between 45 and 75 days after treatment, an earlier peak in maximum mean testicular diameter and an earlier onset of sperm presence in ejaculates.

title: Annual cycle of liveweight and reproductive changes of farmed male fallow deer (Dama dama) and the effect of daily oral administration of XXXX in summer on the attainment of seasonal fertility.

answer: @entity1


abstract: RATIONALE: Cross-species quantification of physiological behavior enables a better understanding of the biological systems underlying @entity2 such as @entity3 ( @entity3 ). Cardinal symptoms of @entity3 include increased motor activity and goal-directed behavior, thought to be related to increased @entity9 activity, potentially selective to @entity4 homeostatic dysregulation. OBJECTIVES: The objective of this study was to test whether acute administration of @entity8 , a @entity5 / @entity4 transporter inhibitor and @entity4 releaser, would replicate the profile of activity and exploration observed in both @entity0 with @entity3 and @entity1 models of @entity3 . METHODS: Healthy volunteers with no @entity2 history were randomized to a one-time dose of placebo (n   =   25), 10  mg @entity6 (n   =   18), or 20  mg @entity8 (n   =   23). Eighty @entity1 were administered one of four doses of @entity6 or vehicle. @entity0 and @entity1 were tested in the behavioral pattern monitor (BPM), which quantifies motor activity, exploratory behavior, and spatial patterns of behavior. RESULTS: In @entity0 , the 20-mg dose of @entity8 increased motor activity as measured by acceleration without marked effects on exploration or spatial patterns of activity. In @entity1 , @entity8 increased activity, decreased specific exploration, and caused straighter, one-dimensional movements in a dose-dependent manner. CONCLUSIONS: Consistent with @entity1 , @entity8 increased motoric activity in @entity0 without increasing exploration. Given that @entity3 @entity0 exhibit heightened exploration, these data further emphasize the limitation of @entity8 -induced @entity7 as a suitable model for @entity3 . Further, these studies highlight the utility of cross-species physiological paradigms in validating biological mechanisms of @entity2 .

title: @entity8 increases activity but not exploration in XXXX and @entity1 .

answer: @entity0


abstract: RATIONALE: Cross-species quantification of physiological behavior enables a better understanding of the biological systems underlying @entity2 such as @entity3 ( @entity3 ). Cardinal symptoms of @entity3 include increased motor activity and goal-directed behavior, thought to be related to increased @entity9 activity, potentially selective to @entity4 homeostatic dysregulation. OBJECTIVES: The objective of this study was to test whether acute administration of @entity8 , a @entity5 / @entity4 transporter inhibitor and @entity4 releaser, would replicate the profile of activity and exploration observed in both @entity0 with @entity3 and @entity1 models of @entity3 . METHODS: Healthy volunteers with no @entity2 history were randomized to a one-time dose of placebo (n   =   25), 10  mg @entity6 (n   =   18), or 20  mg @entity8 (n   =   23). Eighty @entity1 were administered one of four doses of @entity6 or vehicle. @entity0 and @entity1 were tested in the behavioral pattern monitor (BPM), which quantifies motor activity, exploratory behavior, and spatial patterns of behavior. RESULTS: In @entity0 , the 20-mg dose of @entity8 increased motor activity as measured by acceleration without marked effects on exploration or spatial patterns of activity. In @entity1 , @entity8 increased activity, decreased specific exploration, and caused straighter, one-dimensional movements in a dose-dependent manner. CONCLUSIONS: Consistent with @entity1 , @entity8 increased motoric activity in @entity0 without increasing exploration. Given that @entity3 @entity0 exhibit heightened exploration, these data further emphasize the limitation of @entity8 -induced @entity7 as a suitable model for @entity3 . Further, these studies highlight the utility of cross-species physiological paradigms in validating biological mechanisms of @entity2 .

title: XXXX increases activity but not exploration in @entity0 and @entity1 .

answer: @entity8


abstract: RATIONALE: Cross-species quantification of physiological behavior enables a better understanding of the biological systems underlying @entity2 such as @entity3 ( @entity3 ). Cardinal symptoms of @entity3 include increased motor activity and goal-directed behavior, thought to be related to increased @entity9 activity, potentially selective to @entity4 homeostatic dysregulation. OBJECTIVES: The objective of this study was to test whether acute administration of @entity8 , a @entity5 / @entity4 transporter inhibitor and @entity4 releaser, would replicate the profile of activity and exploration observed in both @entity0 with @entity3 and @entity1 models of @entity3 . METHODS: Healthy volunteers with no @entity2 history were randomized to a one-time dose of placebo (n   =   25), 10  mg @entity6 (n   =   18), or 20  mg @entity8 (n   =   23). Eighty @entity1 were administered one of four doses of @entity6 or vehicle. @entity0 and @entity1 were tested in the behavioral pattern monitor (BPM), which quantifies motor activity, exploratory behavior, and spatial patterns of behavior. RESULTS: In @entity0 , the 20-mg dose of @entity8 increased motor activity as measured by acceleration without marked effects on exploration or spatial patterns of activity. In @entity1 , @entity8 increased activity, decreased specific exploration, and caused straighter, one-dimensional movements in a dose-dependent manner. CONCLUSIONS: Consistent with @entity1 , @entity8 increased motoric activity in @entity0 without increasing exploration. Given that @entity3 @entity0 exhibit heightened exploration, these data further emphasize the limitation of @entity8 -induced @entity7 as a suitable model for @entity3 . Further, these studies highlight the utility of cross-species physiological paradigms in validating biological mechanisms of @entity2 .

title: @entity8 increases activity but not exploration in @entity0 and XXXX .

answer: @entity1


abstract: A 35-year-old @entity0 with a history of @entity4 , was presented to our hospital because of @entity10 and @entity12 , 14 days after in vitro fertilization. She received an embryo transfer under controlled ovarian hyper-stimulation. Magnetic resonance images revealed acute @entity9 in the cerebellum and brainstem. Magnetic resonance angiography showed a basilar @entity5 at the end point. Following immediate intravenous rt-PA treatment, the symptoms disappeared completely. A transesophageal echocardiography revealed an @entity3 with a continuous @entity7 . In addition, a Valsalva maneuver trans-esophageal echocardiography with injected saline showed the presence of jet bubbles in the left atrium crossing via the @entity3 . She was diagnosed with @entity6 . Anticoagulant therapy was continued and she gave birth to a healthy baby. @entity8 was associated with the @entity1 that occurred during @entity4 treatment. As anti-phospholipid antibodies were weakly positive, the possibility of @entity11 was suggested. If a @entity0 of childbearing age is presented because of @entity2 , it is important to administer initial therapy by keeping fertility in mind. Thrombolytic therapy for pregnant @entity0 should be carefully considered, because of the associated hazards; however, it is a very important treatment for maternal function after birth. (Received March25, 2015; Accepted May 27, 2015; Published October 1, 2015).

title: [A Case of Paradoxical XXXX Developed during in vitro Fertilization Treatment].

answer: @entity6


abstract: BACKGROUND: Quality of life is an important parameter for quality assurance of the results. After radical prostatectomy, quality of life is often limited. The degree of @entity1 correlates significantly with quality of life. RESULTS: Oncological and functional results are significantly decreased with the age of the @entity0 . On the other hand, the @entity2 of younger @entity0 is significantly greater than in the elderly. In the relative short period of 3-4 weeks of an inpatient rehabilitation in our urology competence center for rehabilitation, the mean decrease of urinary loss (24-h pad test) was 44.4   %. @entity2 also decreased significantly as measured by the questionnaire on @entity2 FBK-R10 (p   <   0.001). CONCLUSIONS: With this, quality of life significantly increased in all function and symptom scales of the QLQ-C30. Thus, this makes reintegration into social life easier. The return to work rate of employed @entity0 after our specific urological rehabilitation program following radical prostatectomy was 87   %.

title: [Quality of life, XXXX , and social outcomes after radical prostatectomy : Results from a urology competence center for rehabilitation].

answer: @entity2


abstract: UNASSIGNED: @entity5 ) has been increasingly detected in @entity2 ( @entity2 ), and genetic polymorphisms in HCMV affect its pathogenesis. This study aimed to investigate HCMV genetic polymorphisms in @entity2 and its correlation with the clinical outcomes. We performed PCR and sequencing of a viral immunomodulatory gene, @entity7 , in clinical isolates and @entity2 specimens. The @entity4 and @entity3 sequences were aligned, and a phylogenetic tree was constructed. The clinical, pathological, and survival data were compared among @entity1 with different @entity7 genotypes. HCMV was detected in 49 (47.8%) of the @entity1 specimens. Genotype A predominated in 43 samples (22/43; 51.2%) with successful sequencing, followed by genotype B (13/43; 30.2%) and genotype C (8/43; 18.6%). The genotypic distribution was similar to that of the clinical isolates and those reported in other Asian populations. The @entity3 sequence of genotype B was the most conserved. For stage II and III @entity2 @entity0 with @entity1 , disease-free survival (DFS) varied amongst the 3 major genotypes (p = 0.0046). The presence of genotype @entity6 in the @entity1 was associated with a shorter DFS and independently predicted @entity1 recurrence in a multivariate Cox proportional hazards model (hazard ratio, 5.79; 95% confidence interval, 1.30-25.81; p = 0.021). By reverse-transcription PCR, @entity1 samples with genotype B viruses had the highest rate of @entity7 expression. Our results suggest that genetic polymorphisms of HCMV @entity7 were associated with clinical outcome in @entity2 and that HCMV may plays an immunomodulatory role in the @entity1 microenvironment of @entity2 .

title: Genetic polymorphisms of the @entity5 @entity7 gene in XXXX and its association with clinical outcome.

answer: @entity2


abstract: UNASSIGNED: @entity5 ) has been increasingly detected in @entity2 ( @entity2 ), and genetic polymorphisms in HCMV affect its pathogenesis. This study aimed to investigate HCMV genetic polymorphisms in @entity2 and its correlation with the clinical outcomes. We performed PCR and sequencing of a viral immunomodulatory gene, @entity7 , in clinical isolates and @entity2 specimens. The @entity4 and @entity3 sequences were aligned, and a phylogenetic tree was constructed. The clinical, pathological, and survival data were compared among @entity1 with different @entity7 genotypes. HCMV was detected in 49 (47.8%) of the @entity1 specimens. Genotype A predominated in 43 samples (22/43; 51.2%) with successful sequencing, followed by genotype B (13/43; 30.2%) and genotype C (8/43; 18.6%). The genotypic distribution was similar to that of the clinical isolates and those reported in other Asian populations. The @entity3 sequence of genotype B was the most conserved. For stage II and III @entity2 @entity0 with @entity1 , disease-free survival (DFS) varied amongst the 3 major genotypes (p = 0.0046). The presence of genotype @entity6 in the @entity1 was associated with a shorter DFS and independently predicted @entity1 recurrence in a multivariate Cox proportional hazards model (hazard ratio, 5.79; 95% confidence interval, 1.30-25.81; p = 0.021). By reverse-transcription PCR, @entity1 samples with genotype B viruses had the highest rate of @entity7 expression. Our results suggest that genetic polymorphisms of HCMV @entity7 were associated with clinical outcome in @entity2 and that HCMV may plays an immunomodulatory role in the @entity1 microenvironment of @entity2 .

title: Genetic polymorphisms of the @entity5 XXXX gene in @entity2 and its association with clinical outcome.

answer: @entity7


abstract: UNASSIGNED: @entity5 ) has been increasingly detected in @entity2 ( @entity2 ), and genetic polymorphisms in HCMV affect its pathogenesis. This study aimed to investigate HCMV genetic polymorphisms in @entity2 and its correlation with the clinical outcomes. We performed PCR and sequencing of a viral immunomodulatory gene, @entity7 , in clinical isolates and @entity2 specimens. The @entity4 and @entity3 sequences were aligned, and a phylogenetic tree was constructed. The clinical, pathological, and survival data were compared among @entity1 with different @entity7 genotypes. HCMV was detected in 49 (47.8%) of the @entity1 specimens. Genotype A predominated in 43 samples (22/43; 51.2%) with successful sequencing, followed by genotype B (13/43; 30.2%) and genotype C (8/43; 18.6%). The genotypic distribution was similar to that of the clinical isolates and those reported in other Asian populations. The @entity3 sequence of genotype B was the most conserved. For stage II and III @entity2 @entity0 with @entity1 , disease-free survival (DFS) varied amongst the 3 major genotypes (p = 0.0046). The presence of genotype @entity6 in the @entity1 was associated with a shorter DFS and independently predicted @entity1 recurrence in a multivariate Cox proportional hazards model (hazard ratio, 5.79; 95% confidence interval, 1.30-25.81; p = 0.021). By reverse-transcription PCR, @entity1 samples with genotype B viruses had the highest rate of @entity7 expression. Our results suggest that genetic polymorphisms of HCMV @entity7 were associated with clinical outcome in @entity2 and that HCMV may plays an immunomodulatory role in the @entity1 microenvironment of @entity2 .

title: Genetic polymorphisms of the XXXX @entity7 gene in @entity2 and its association with clinical outcome.

answer: @entity5


abstract: The present study evaluates the effect of an intravenous (i.v.) @entity4 infusion on total and ionized @entity1 . Seven groups of @entity0 were studied, and it was found that the magnitude of @entity3 was dose dependent. During a two hour i.v. infusion containing 0.4 mg @entity4 per 100 grams of body weight, the total plasma @entity1 increased from 9.7 +/- 0.2 to 12.7 +/- 0.7 mg/dl (X +/- SE, P less than 0.02) while the ionized @entity1 decreased from 5.1 +/- 0.12 to 4.05 +/- 0.24 mg/dl (P less than 0.001). The increase in plasma @entity1 occurred in intact and parathyroidectomized @entity0 , and the @entity3 could not be attributed to changes in @entity5 , arterial pH, plasma protein, or plasma @entity2 . In vitro studies indicate that the addition of @entity4 to @entity0 plasma results in decreased ionized @entity1 concentration. Similarly, ultrafilterable @entity1 declined from 5.4 +/- 0.17 to 4.53 +/- 0.12 mg/dl (P less than 0.001) after the addition of @entity4 to @entity0 plasma. In summary, high levels of intravenous @entity4 increase total plasma @entity1 and decrease ionized @entity1 . As also supported by in vitro data, the most probable mechanism is increased binding of @entity1 in the plasma which decreases ionized @entity1 . As a result of the decreased concentration of ionized @entity1 , movement of bone and interstitial @entity1 into the vascular space may occur, thus increasing total plasma @entity1 .

title: The role of XXXX in the development of @entity3 in the @entity0 .

answer: @entity4


abstract: The present study evaluates the effect of an intravenous (i.v.) @entity4 infusion on total and ionized @entity1 . Seven groups of @entity0 were studied, and it was found that the magnitude of @entity3 was dose dependent. During a two hour i.v. infusion containing 0.4 mg @entity4 per 100 grams of body weight, the total plasma @entity1 increased from 9.7 +/- 0.2 to 12.7 +/- 0.7 mg/dl (X +/- SE, P less than 0.02) while the ionized @entity1 decreased from 5.1 +/- 0.12 to 4.05 +/- 0.24 mg/dl (P less than 0.001). The increase in plasma @entity1 occurred in intact and parathyroidectomized @entity0 , and the @entity3 could not be attributed to changes in @entity5 , arterial pH, plasma protein, or plasma @entity2 . In vitro studies indicate that the addition of @entity4 to @entity0 plasma results in decreased ionized @entity1 concentration. Similarly, ultrafilterable @entity1 declined from 5.4 +/- 0.17 to 4.53 +/- 0.12 mg/dl (P less than 0.001) after the addition of @entity4 to @entity0 plasma. In summary, high levels of intravenous @entity4 increase total plasma @entity1 and decrease ionized @entity1 . As also supported by in vitro data, the most probable mechanism is increased binding of @entity1 in the plasma which decreases ionized @entity1 . As a result of the decreased concentration of ionized @entity1 , movement of bone and interstitial @entity1 into the vascular space may occur, thus increasing total plasma @entity1 .

title: The role of @entity4 in the development of XXXX in the @entity0 .

answer: @entity3


abstract: The present study evaluates the effect of an intravenous (i.v.) @entity4 infusion on total and ionized @entity1 . Seven groups of @entity0 were studied, and it was found that the magnitude of @entity3 was dose dependent. During a two hour i.v. infusion containing 0.4 mg @entity4 per 100 grams of body weight, the total plasma @entity1 increased from 9.7 +/- 0.2 to 12.7 +/- 0.7 mg/dl (X +/- SE, P less than 0.02) while the ionized @entity1 decreased from 5.1 +/- 0.12 to 4.05 +/- 0.24 mg/dl (P less than 0.001). The increase in plasma @entity1 occurred in intact and parathyroidectomized @entity0 , and the @entity3 could not be attributed to changes in @entity5 , arterial pH, plasma protein, or plasma @entity2 . In vitro studies indicate that the addition of @entity4 to @entity0 plasma results in decreased ionized @entity1 concentration. Similarly, ultrafilterable @entity1 declined from 5.4 +/- 0.17 to 4.53 +/- 0.12 mg/dl (P less than 0.001) after the addition of @entity4 to @entity0 plasma. In summary, high levels of intravenous @entity4 increase total plasma @entity1 and decrease ionized @entity1 . As also supported by in vitro data, the most probable mechanism is increased binding of @entity1 in the plasma which decreases ionized @entity1 . As a result of the decreased concentration of ionized @entity1 , movement of bone and interstitial @entity1 into the vascular space may occur, thus increasing total plasma @entity1 .

title: The role of @entity4 in the development of @entity3 in the XXXX .

answer: @entity0


abstract: Microporous, compliant, biodegradable vascular grafts prepared from a mixture of @entity2 (95% weight) and @entity3 (5% weight) can function as a temporary scaffold for the regeneration of the arterial wall in small-caliber arteries. This study was undertaken to document the sequential events leading to this regeneration. Therefore, @entity2 / @entity3 vascular grafts were implanted into the abdominal aorta of @entity0 (N = 28) and were harvested at regular intervals from 1 hour up to 12 weeks after implantation. The implants were evaluated by means of light and electron microscopy. At each time of harvesting, the implants were patent and showed arterial pulsations. No @entity1 or dilatation was observed. Endothelial cells grew from the adjacent aortic intima across the anastomoses, from day 6 onward, to form an almost complete @entity4 after 6 weeks of implantation. Smooth muscle cells also grew from the adjacent aortic media over the graft lattice through the platelet-fibrin coagulum from day 6 onward. The smooth muscle cells, predominantly longitudinally arranged at week 6, but also circularly arranged in some areas at week 12, formed a neomedia in which elastic laminae regenerated. Polymorphonuclear leukocytes and monocytes initially invaded the graft lattices. Fibroblasts, histiocytes, and capillaries grew from the perigraft tissue into the @entity2 / @entity3 lattices from day 6 onward, which resulted in the formation of a neoadventitia. The @entity2 / @entity3 lattices started to disintegrate from day 12 onward. The regenerative processes in the disintegrating @entity2 / @entity3 grafts resulted in the formation of neoarteries, which were of sufficient strength, compliance, and thromboresistance to function as small-caliber arterial substitutes.

title: Sequential studies of arterial wall regeneration in microporous, compliant, biodegradable small-caliber vascular grafts in XXXX .

answer: @entity0


abstract: 1. An investigation has been made of the changes occurring in lysosomal enzyme activities during the early development of experimentally produced @entity2 in the @entity0 . Three enzymes have been studied: acid phosphatase, acid ribonuclease and beta-glucuronidase. Four different methods of inducing @entity2 have been used: administration of @entity4 , @entity5 , @entity3 and the fungal toxin sporidesmin. 2. The majority of the data presented concern alterations produced by @entity4 . Despite the extensive central @entity1 and accompanying fat accumulation which this poison produced in the liver, only small changes in the activity and latency of lysosomal enzymes could be detected. In the early (pre-necrotic) period of injury these changes were insignificant. At a late stage of injury, when @entity1 was present, there were indications of lysosomal rupture. 3. The results obtained with the other three hepatotoxins were similar to those described for @entity4 in that no evidence of early lysosomal rupture was obtained during the pre-necrotic period. It is concluded that lysosomes probably play no role in the early development of the four types of @entity2 studied but, instead, are involved in later scavenging processes.

title: Changes in lysosomal enzymes in acute experimental XXXX .

answer: @entity2


abstract: In a prospective study, 112 fresh @entity2 samples were collected from 83 consecutive @entity0 . Cellular DNA content was measured by flow cytometry. All the benign (n = 24) and semimalignant (n = 6) @entity1 were diploid. Of 50 @entity1 , 24 (48%) were diploid and 26 (52%) were @entity4 . Aneuploidy was more frequent in the advanced stages of the disease, in @entity1 of low degree of differentiation, and in older @entity0 . The @entity0 with @entity1 had smaller @entity1 and more often ascites. The fraction of cells with S-phase DNA content was higher in the @entity1 . No association was seen to the @entity1 type. Ploidy determination is objective and reproducible. Aneuploidy associates to most negative prognostic factors in @entity2 and may reflect the @entity3 . The ploidy status may be taken into consideration in the stratification of @entity0 of comparable risk for treatment studies.

title: Ploidy assessment of benign and malignant XXXX by flow cytometry. A clinicopathologic study.

answer: @entity2


abstract: Eight reversible inhibitors were used to study decreases in lymphocyte capping in @entity0 with @entity6 ( @entity6 ) when compared to controls. The inhibitors included @entity2 , @entity7 , @entity1 ionophore, @entity9 , @entity4 , @entity10 , @entity5 and @entity8 . All of these inhibitors disrupt cap formation. Mononuclear leukocytes from @entity6 @entity0 and controls were isolated from whole blood, incubated with @entity3 -conjugated polyvalent antisera and inhibitor, induced to form caps, and the caps counted using a fluorescent microscope. Cell viabilities and morphology were assessed. After removal of inhibitor, the cells were recounted. All of the inhibitors significantly lowered capping in controls (p less than 0.001), but this effect was seen with only four out of the eight inhibitors in @entity6 @entity0 . @entity10 and @entity8 were less inhibitory in @entity0 (p less than 0.005, p greater than 0.05, and p greater than 0.05 respectively) while capping in @entity0 was not inhibited by @entity5 and @entity2 (p greater than 0.5). The lack of @entity2 inhibition suggests that the differences in capping between @entity6 @entity0 and controls may lie within the membrane itself, rather than its associated components (i.e. cytoskeletal network), and that the defect occurs toward the beginning of the capping sequence.

title: Systemic membrane defect and the inhibition of lymphocyte capping in XXXX .

answer: @entity6


abstract: 120 @entity0 with the first occurrence of @entity5 stage Ta or T1 @entity2 were given adjuvant intravesical treatment in 2 consecutive series. The first 60 received @entity3 monthly for 6 months, then on the 9th and 12th month following surgery. The second series was given @entity4 weekly for 2 months, then monthly to the end of the first year. Median follow-up is 48 months in the first series and 15 in the second. In the @entity3 group, 28 @entity0 had recurrences. The recurrence rate is 1.86/100 @entity0 -months. Seventeen of these first relapses occurred within the first year. In the 'intensive' @entity4 series, where 36 @entity0 were observed for 12 months or more, 3 relapsed. The recurrence rate to date is 0.35. The relapse-free survival probability at 12 months is 75% in the first series and 93% in the second. Treatment was stopped due to @entity1 in 4 @entity0 in the @entity3 group and in 10 of the @entity4 group.

title: Adjuvant intravesical chemotherapy of superficial @entity2 with monthly @entity3 or intensive XXXX . A comparison of two consecutive series.

answer: @entity4


abstract: 120 @entity0 with the first occurrence of @entity5 stage Ta or T1 @entity2 were given adjuvant intravesical treatment in 2 consecutive series. The first 60 received @entity3 monthly for 6 months, then on the 9th and 12th month following surgery. The second series was given @entity4 weekly for 2 months, then monthly to the end of the first year. Median follow-up is 48 months in the first series and 15 in the second. In the @entity3 group, 28 @entity0 had recurrences. The recurrence rate is 1.86/100 @entity0 -months. Seventeen of these first relapses occurred within the first year. In the 'intensive' @entity4 series, where 36 @entity0 were observed for 12 months or more, 3 relapsed. The recurrence rate to date is 0.35. The relapse-free survival probability at 12 months is 75% in the first series and 93% in the second. Treatment was stopped due to @entity1 in 4 @entity0 in the @entity3 group and in 10 of the @entity4 group.

title: Adjuvant intravesical chemotherapy of superficial @entity2 with monthly XXXX or intensive @entity4 . A comparison of two consecutive series.

answer: @entity3


abstract: 120 @entity0 with the first occurrence of @entity5 stage Ta or T1 @entity2 were given adjuvant intravesical treatment in 2 consecutive series. The first 60 received @entity3 monthly for 6 months, then on the 9th and 12th month following surgery. The second series was given @entity4 weekly for 2 months, then monthly to the end of the first year. Median follow-up is 48 months in the first series and 15 in the second. In the @entity3 group, 28 @entity0 had recurrences. The recurrence rate is 1.86/100 @entity0 -months. Seventeen of these first relapses occurred within the first year. In the 'intensive' @entity4 series, where 36 @entity0 were observed for 12 months or more, 3 relapsed. The recurrence rate to date is 0.35. The relapse-free survival probability at 12 months is 75% in the first series and 93% in the second. Treatment was stopped due to @entity1 in 4 @entity0 in the @entity3 group and in 10 of the @entity4 group.

title: Adjuvant intravesical chemotherapy of superficial XXXX with monthly @entity3 or intensive @entity4 . A comparison of two consecutive series.

answer: @entity2


abstract: Despite recent advances in surgical technique and refractive correction, amblyopia remains a significant problem in the treatment of monocular infantile @entity1 . Amblyopia therapy recommended by different authors during the preverbal period has varied from no patching to nearly full-time occlusion of the phakic eye. We measured preferential looking (PL) acuities sequentially in four @entity0 following monocular @entity1 surgery and contact lens correction. This information was used to adjust occlusion of the phakic eye, which was prescribed 25%-100% of waking hours. Patching schedules were altered, on average, every three to four months in response to changes in PL acuities. Four increases in patching intensity retarded acuity development in the phakic and benefited development in the aphakic eyes. Nine decreases enhanced progress or yielded no change in the phakic and, with two exceptions, impeded progress in the aphakic eyes. Recognition acuities now available for two of the @entity0 show continuity with previous PL acuities and confirm useful vision in the aphakic eyes. We describe guidelines for adjusting occlusion based on our experience. We believe that PL modulation of patching therapy may result in more favorable visual outcomes for both eyes of @entity0 with monocular @entity1 .

title: Preferential looking as a guide for amblyopia therapy in monocular infantile XXXX .

answer: @entity1


abstract: Tracheal and gastric aspirates from premature @entity0 simultaneously sampled shortly after birth were analyzed for their phospholipid composition using 2-dimensional thin layer chromatography. The results were related to clinical outcome. The L/S ratio was higher in @entity0 without than in @entity0 with @entity2 ( @entity2 ). The L/S values and the concentrations of @entity1 (PG) were higher in tracheal compared with gastric aspirates (table I). This resulted in different L/S cutoff points with respect to lung maturity. In both aspirates, the predictive value of a "mature" (but not of an "immature") L/S ratio was improved by PG determination (table II). Only one out of 22 @entity0 with @entity2 had a completely "mature" phospholipid profile in its tracheal aspirate. Two vaginally delivered premature @entity0 without @entity2 had an "immature" phospholipid pattern in their gastric aspirates, but a "mature" one in their tracheal aspirates. The results indicate that phospholipid analysis of tracheal and gastric aspirates shortly after birth is useful in the biochemical diagnosis of @entity2 if proper cutoff points for the L/S ratio are used and the determination of PG is included. It may prove to be important in establishing criteria for a therapeutic trial of surfactant substitution.

title: The role of XXXX in phospholipid analysis of tracheal and gastric aspirate in premature @entity0 .

answer: @entity1


abstract: Tracheal and gastric aspirates from premature @entity0 simultaneously sampled shortly after birth were analyzed for their phospholipid composition using 2-dimensional thin layer chromatography. The results were related to clinical outcome. The L/S ratio was higher in @entity0 without than in @entity0 with @entity2 ( @entity2 ). The L/S values and the concentrations of @entity1 (PG) were higher in tracheal compared with gastric aspirates (table I). This resulted in different L/S cutoff points with respect to lung maturity. In both aspirates, the predictive value of a "mature" (but not of an "immature") L/S ratio was improved by PG determination (table II). Only one out of 22 @entity0 with @entity2 had a completely "mature" phospholipid profile in its tracheal aspirate. Two vaginally delivered premature @entity0 without @entity2 had an "immature" phospholipid pattern in their gastric aspirates, but a "mature" one in their tracheal aspirates. The results indicate that phospholipid analysis of tracheal and gastric aspirates shortly after birth is useful in the biochemical diagnosis of @entity2 if proper cutoff points for the L/S ratio are used and the determination of PG is included. It may prove to be important in establishing criteria for a therapeutic trial of surfactant substitution.

title: The role of @entity1 in phospholipid analysis of tracheal and gastric aspirate in premature XXXX .

answer: @entity0


abstract: We report a retrospective study of 52 @entity0 with unresectable @entity2 of the esophagus treated with substernal bypass without resection. There were 49 @entity7 and 3 @entity6 . The site of the @entity1 was the middle third of the esophagus in 32 @entity0 , the upper third in 9, and the lower third in 11. The diagnosis of inextirpability was made preoperatively in 34 @entity0 and at laparotomy in 18. Thoracotomy was never performed. The bypass procedure was ileocolic in 22 cases and gastric in 30 cases. No @entity0 had postoperative chemotherapy or radiation therapy. The operative mortality rate was 9.6 p. 100 (5 cases) and the hospital mortality was 19.2 p. 100 (10 cases). Morbidity was 46 p. 100. Twenty-two cervical @entity4 occurred; 19 closed spontaneously. Eighteen endoscopic dilatations and four reoperations were performed for 22 secondary stenoses of the cervical @entity3 . Median survival rate was 6.2 months. We conclude that substernal bypass is a valuable alternative for palliation of @entity5 but that its indications should be limited.

title: [Is the palliative treatment of XXXX by retrosternal bypass justified?].

answer: @entity1


abstract: Twenty-four premature fetal @entity3 underwent tracheotomy (n = 11) or endotracheal intubation (n = 13) for 3-9 h for an unrelated experiment. All were maintained with 100% @entity1 on a pressure cycled ventilator. No suctioning was performed. At sacrifice, sections of the distal @entity4 were studied for histopathological changes in epithelium, @entity6 . All changes were confined to the epithelium and were reported as either @entity7 in regards to preservation of the basal cell layer. In tracheotomized and intubated animals, both @entity5 were seen as early as 3 and 3.5 h, respectively. In the intubated animals, 13.5% of the cumulative tracheal circumference showed total @entity5 ; 19.8% showed partial @entity5 . In animals undergoing tracheotomy, 9.6% of the cumulative tracheal circumference had total @entity5 ; 19.1% had partial @entity5 . Possible etiological factors include @entity1 @entity2 , lack of humidification, effects of mechanical ventilation and indirect trauma from surgery or intubation. The clinical significance for premature @entity0 is discussed.

title: A quantitative comparison of the early histopathological changes from tracheotomy and endotracheal intubation on the distal @entity4 in fetal XXXX .

answer: @entity3


abstract: Twenty-four premature fetal @entity3 underwent tracheotomy (n = 11) or endotracheal intubation (n = 13) for 3-9 h for an unrelated experiment. All were maintained with 100% @entity1 on a pressure cycled ventilator. No suctioning was performed. At sacrifice, sections of the distal @entity4 were studied for histopathological changes in epithelium, @entity6 . All changes were confined to the epithelium and were reported as either @entity7 in regards to preservation of the basal cell layer. In tracheotomized and intubated animals, both @entity5 were seen as early as 3 and 3.5 h, respectively. In the intubated animals, 13.5% of the cumulative tracheal circumference showed total @entity5 ; 19.8% showed partial @entity5 . In animals undergoing tracheotomy, 9.6% of the cumulative tracheal circumference had total @entity5 ; 19.1% had partial @entity5 . Possible etiological factors include @entity1 @entity2 , lack of humidification, effects of mechanical ventilation and indirect trauma from surgery or intubation. The clinical significance for premature @entity0 is discussed.

title: A quantitative comparison of the early histopathological changes from tracheotomy and endotracheal intubation on the distal XXXX in fetal @entity3 .

answer: @entity4


abstract: Activation of the complement system to completion results either in the generation of a pore-forming, cytolytic C5b-9(m) complex, or of a cytolytically inactive, fluid-phase SC5b-9 complex. In this paper, we describe a sensitive and reliable, sandwich ELISA for C5b-9(m) and SC5b-9, which is based on the use of a monoclonal antibody to a neoantigen of C5b-9 in combination with affinity-purified, polyclonal rabbit antibodies. The ELISA has been calibrated with purified C5b-9(m) and SC5b-9, and can detect 3 ng/ml C5b-9(m) and 20 ng/ml SC5b-9. We show that maximal conversion of C5-C9 in pooled human serum by insulin or zymosan activation generates 220 +/- 40 micrograms/ml SC5b-9. 65 of 100 normal @entity0 @entity4 plasma samples analyzed in this study contained 100-600 ng/ml SC5b-9, corresponding to 0.04-0.24% of maximal conversion. Levels of circulating SC5b-9 in other donors were below the limit of detection. Incubation of serum at 37 degrees C always led to spontaneous generation of SC5b-9; concentrations ranged from 490-4725 ng/ml after 60 min, 37 degrees C, with a mean of 1848 +/- 1031 (SD) ng/ml amongst 25 donors studied. The terminal complement complex present in @entity4 plasma was partially purified by @entity3 precipitation, @entity6 -ion exchange chromatography and @entity2 density gradient centrifugation, and was found to contain C8, C9 and @entity5 as demonstrable by @entity1 -PAGE immunoblotting. Thus, the material most probably represented genuine SC5b-9. No significant age- or sex-dependent variations in SC5b-9 levels were noted. The present data call for a critical re-appraisal of several previously published methods for the determination of SC5b-9 levels in @entity0 plasma and serum.

title: Sensitive ELISA for quantitating the terminal membrane C5b-9 and fluid-phase SC5b-9 complex of XXXX complement.

answer: @entity0


abstract: A 41-year-old male with incomplete type of Beh  et's disease was operated on because of @entity3 of the thoraco-abdominal aorta. A saccular @entity4 developed by rupture of the aortic wall involved the left postero-lateral portion of the supra-renal abdominal aorta. The defect in the @entity2 was closed using Dacron patch. The post-operative course was uneventful. However, seven months after discharge, the @entity0 developed severe back @entity1 at midnight, and was referred to our institution. On physical examination, a pulsatile mass was found in the right epigastric area. CT and DSA showed saccular @entity4 at the patch anastomotic site. Extra-anatomic long bypass grafting was performed from the ascending aorta to the infra-renal abdominal aorta. The abdominal aorta was occluded just below the diaphragm and the supra-renal portion of the aorta. Reconstruction of coeliac artery and superior mesenteric artery was made using branch grafts attached to the long graft. Surgical treatment of the complicated Beh  et's disease should include extra-anatomic bypass, especially in the re-operative cases of @entity3 of the aorta.

title: [A case of XXXX of the thoraco-abdominal aorta associated with Beh  et's disease].

answer: @entity3


abstract: OBJECTIVES: Our objective was to determine the impact that a @entity0 's geographic status has on the efficacy of first-time @entity1 maintenance therapy (MMT) retention. METHODS: We conducted an observational cohort study using administrative health care databases for @entity0 who commenced @entity1 therapy between 2003 and 2012. @entity0 were stratified on the basis of their location of residence into 1 of 4 groups-Southern Urban, Southern Rural, Northern Urban, or Northern Rural. The primary outcome was continuous retention in treatment, defined as 1 year of uninterrupted therapy on the basis of prescription refill data. Mortality was measured as a secondary outcome. RESULTS: We identified 17,211 @entity0 initiating first-time MMT during this 10-year period. Nearly half of @entity0 initiating therapy in northern regions completed 1 year of treatment (48.9%; N=258 and 47.0%; N=761 in Northern Rural and Urban regions, respectively), whereas lower rates of 40.6% (N=410) and 39.3% (N=5,518) occurred in Southern Rural and Urban regions, respectively. @entity0 residing in Northern Rural and Northern Urban regions were 31% (adjusted odds ratio=1.31; 95% confidence interval [CI], 1.09%-1.58%] and 14% (adjusted odds ratio=1.14; 95% CI, 1.02%-1.27%] more likely to be retained in treatment compared with those residing in Southern Urban regions. There was no significant difference in treatment retention between those residing in Southern Rural and Southern Urban regions. A mortality rate of 3% was observed within 1 year of @entity0 initiating treatment, with @entity0 in the Southern Rural region having the highest rate (4.85%). CONCLUSIONS: Our study identified regional differences in retention rates and mortality of first-time MMT. These findings may relate to geographic isolation and limited @entity1 program availability experienced in northern regions. We interpret the data to suggest that @entity0 who have reduced access to treatment experience higher retention rates when they are able to access therapy.

title: Evaluating the Effectiveness of First-Time XXXX Maintenance Therapy Across Northern, Rural, and Urban Regions of Ontario, Canada.

answer: @entity1


abstract: BACKGROUND: @entity3 is a leading cause of @entity6 among kidney transplant recipients. @entity7 increases the risk for cardiovascular events and decreases graft survival. Lately, guidelines for management of the @entity7 , primarily @entity4 , @entity1 ( @entity1 ) and @entity10 have dramatically changed in an attempt to decrease @entity3 among kidney transplant recipients. In the present study we examined whether these guideline changes had impact on our management of post-transplantation @entity0 and the subsequent treatment outcomes for these diseases. METHODS: Data were obtained from kidney transplant clinic files from two follow-up (FU) periods-between 1994-1997 and between 2008-2011. Demographic data, monitoring and screening frequency for cardiovascular risk factors, immunosuppression regimen, treatment for @entity4 , @entity1 and @entity8 , treatment outcomes and graft function changes were compared between the two follow-up periods. RESULTS: There was a significant increase in the percentage of @entity0 undergoing transplantation due to @entity5 secondary to @entity1 and/or @entity4 . @entity0 monitoring and screening during the second FU period were less frequent, but more targeted, reflecting changes in clinic routines. Blood pressure was better controlled in the second FU period (p  <  0.01), as was @entity10 (p  <  0.001). High fasting @entity9 levels were more prevalent among @entity0 in the second group (p  <  0.005), although more @entity0 received treatment for @entity1 (p  <  0.001). Significantly, fewer @entity0 experienced @entity2 during the second FU period (p  <  0.001). CONCLUSIONS: We found that guideline changes had impact on clinical practice, which translated to better control of the @entity7 . @entity1 control is challenging. Overall, stability of kidney function improved.

title: Implementation of guidelines for XXXX control in kidney transplant recipients: results at a single center.

answer: @entity7


abstract: A retrospective long-term analysis of the results of primary postoperative radiotherapy in 106 @entity0 with @entity3 is presented. Forty-two @entity0 received @entity6 , and 64 received treatment by various subtotal abdominopelvic techniques. The mean follow-up of living @entity0 in the two groups is 86 and 116 months, respectively. @entity0 who had Federation International Gynecology and Oncology (FIGO) stages I through III-A with no postoperative @entity4 , or less than 0.5-cm abdominal and/or less than 2-cm pelvic @entity4 formed a favorable group in whom total abdominopelvic irradiation resulted in a 71% 10-year actuarial relapse-free survival rate compared with 40% for those treated by subtotal abdominopelvic techniques (P less than or equal to .0205). The survival improvement due to the total abdominopelvic technique in favorable @entity0 became even more significant (P less than or equal to 0.003) after adjusting for differences in stage, grade, and postoperative @entity4 volume (no, or favorable, gross). Increasing grade appeared to be associated with decreasing survival even among favorable @entity0 treated with the optimal technique, although the differences did not approach statistical significance after adjusting for @entity4 volume and stage. @entity1 were equivalent, 7.1% for total abdominopelvic v 8.1% for subtotal abdominopelvic techniques. The addition of intraperitoneal radioactive chromic @entity5 increased the surgical bowel complication rate 33% over external pelvic irradiation alone without improving survival. @entity0 with unfavorable gross @entity4 and/or FIGO stages III-B and IV were incurable by any radiation technique. Those with no, or favorable, gross @entity2 constitute a group in whom we believe @entity6 represents a potentially curative therapy modality.

title: Analysis of postoperative radiation therapy in stage I through XXXX .

answer: @entity3


abstract: We studied the interaural phase sensitivity of 85 units in the inferior colliculus (IC) of the unanesthetized @entity0 . We assessed this sensitivity at several frequencies within each unit's responsive range. The interaural phase disparity was varied by delivering tones that differed by 1 Hz to the two ears, resulting in a 1-Hz binaural beat. We analyzed each unit's response to different frequencies by calculating four measures: @entity1 ( @entity1 ), @entity3 ( @entity3 ), composite peak delay, and mean peak delay. We estimated the @entity1 and @entity3 from the slope and phase intercept, respectively, of the regression line fitted to a plot of the mean interaural phase against stimulating frequency. The composite peak delay was estimated from the peak of a composite delay curve. This was generated by replotting the response to changes in interaural phase, as a function of the equivalent interaural delay and averaging the resultant interaural delay curves. The composite delay curve reflects the unit's average response to interaural delays across frequencies. Last, we calculated a mean peak delay, derived by converting the mean interaural phase of the response at each frequency to an equivalent delay and then averaging these delays. Interaural phase sensitivity was observed to frequencies as high as 2,150 Hz. However, the majority of units showed such sensitivity below 1,500 Hz. For most units, the interaural delay curves measured at several frequencies coincided near the peak discharge. This result is consistent with a neural model, where excitatory inputs from each ear converge upon a binaural cell, evoking maximum discharge only when the two inputs arrive simultaneously. As a first approximation, our data fit this model, indicating that IC neurons can act like coincidence detectors or cross-correlators. The distributions of @entity1 , composite peak delay, and mean peak delay showed that most units preferred @entity2 , which in the natural situation corresponds to sounds emanating from the contralateral field. Moreover, most units preferred delays that were within the estimated physiological range of the @entity0 . These results support the viewpoint that neurons in the IC participate in sound localization. The distributions of @entity3 and @entity1 differ substantially from those found in the IC of the anesthetized cat. These differences may reflect species differences, the effects of anesthesia, or a difference in the population of units sampled. For each unit, we assessed the linearity of the plot of mean interaural phase against frequency of stimulation using a chi 2 method. For most units the plots were significantly nonlinear.(ABSTRACT TRUNCATED AT 400 WORDS)

title: Interaural phase-sensitive units in the inferior colliculus of the unanesthetized XXXX : effects of changing frequency.

answer: @entity0


abstract: The energy and redox states of placentas in newly anesthetized or sacrificed @entity6 and @entity5 were compared with that of @entity0 placentas immediately after delivery. Subsequently the effect of @entity1 was observed in both @entity0 and animal placentas. The influence of perfusion, using a fluid containing oxygenated red cells (adult @entity0 ) was studied in the @entity0 placenta. Adenine @entity2 precursors were added to the perfusion fluid in an attempt to improve the energy and redox states and the mixed protein synthetic rate of the tissue. The @entity7 and @entity10 concentrations in @entity6 placental tissue taken immediately after nembutal anesthesia were 1.16 and 3.59 mmol kg-1 wet weight respectively. One minute's @entity1 caused a fall in @entity7 to 0.7 and a rise in @entity10 to 6.5 mmol kg-1. The concentration of @entity7 in @entity0 placental tissue, 30 secs to 3 minutes after delivery of the organ, was 0.52 and of @entity10 4.8 mmol kg-1 wet weight, suggesting that some biochemical deterioration had already occurred. A further fall in @entity7 to 0.21 and rise in @entity10 to 6.4 mmol kg-1 wet weight took place during 20 mins of @entity1 ; thereafter the @entity7 level remained constant while the @entity10 continued to rise to 11 mmol kg-1 wet weight by 1 1/2 hours. The initial energy charge was similar in both animal and @entity0 placentas, 0.8-0.9, and was only reduced during prolonged @entity4 at 37 degrees C. Since the @entity9 did not rise to the same extent as in other tissues, it is suggested that the Atkinson equation used in the calculation of energy charge may not be applicable to the placenta, and that the most sensitive indication of deterioration in energy status is the @entity3 fall in @entity7 concentration. Rapid establishment of maternal intervillous perfusion of an isolated lobule of the @entity0 placenta using ixygenated RBCS in the perfusion fluid, enabled the @entity7 and @entity10 levels to be maintained near to 'in vivo' values during one hour, with a protein turnover rate of 40% day-1, two thirds of that observed 'in vivo' in the @entity5 . The addition of 1.0-50 microM @entity8 to the perfusion fluid improved the energy state of the tissue, but not its redox state nor protein synthetic rate. 1.5 microM inosine in the perfusion medium did not alter the energy state but caused a marked reduction in @entity10 production.

title: Observations on the energy and redox state and protein synthetic rate in animal and XXXX placentas.

answer: @entity0